Literature DB >> 25436783

Xpert MTB/RIF false detection of rifampin-resistant tuberculosis from prior infection.

J Daniel Kelly1, Shou-Yean Grace Lin, Pennan M Barry, Chris Keh, Julie Higashi, John Z Metcalfe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25436783      PMCID： PMC5446205          DOI： 10.1164/rccm.201408-1500LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  12 in total

1.  Rapid detection of rifampin resistance in Mycobacterium tuberculosis by Pyrosequencing technology.

Authors:  Pontus Jureen; Lars Engstrand; Solveig Eriksson; Anders Alderborn; Margareta Krabbe; Sven E Hoffner
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

2.  Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment.

Authors:  Sven O Friedrich; Andrea Rachow; Elmar Saathoff; Kasha Singh; Chacha D Mangu; Rodney Dawson; Patrick Pj Phillips; Amour Venter; Anna Bateson; Catharina C Boehme; Norbert Heinrich; Robert D Hunt; Martin J Boeree; Alimuddin Zumla; Timothy D McHugh; Stephen H Gillespie; Andreas H Diacon; Michael Hoelscher
Journal:  Lancet Respir Med       Date:  2013-07-01       Impact factor: 30.700

3.  Pyrosequencing for rapid detection of extensively drug-resistant Mycobacterium tuberculosis in clinical isolates and clinical specimens.

Authors:  S-Y Grace Lin; Timothy C Rodwell; Thomas C Victor; Errin C Rider; Lucy Pham; Antonino Catanzaro; Edward P Desmond
Journal:  J Clin Microbiol       Date:  2013-11-27       Impact factor: 5.948

4.  False-positive Xpert® MTB/RIF assays in previously treated patients: need for caution in interpreting results.

Authors:  T H Boyles; J Hughes; V Cox; R Burton; G Meintjes; M Mendelson
Journal:  Int J Tuberc Lung Dis       Date:  2014-07       Impact factor: 2.373

5.  Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia.

Authors:  M Ruddy; Y Balabanova; C Graham; I Fedorin; N Malomanova; E Elisarova; S Kuznetznov; G Gusarova; S Zakharova; A Melentyev; E Krukova; V Golishevskaya; V Erokhin; I Dorozhkova; F Drobniewski
Journal:  Thorax       Date:  2005-02       Impact factor: 9.139

6.  False-positive rifampicin resistance on Xpert® MTB/RIF: case report and clinical implications.

Authors:  A Van Rie; K Mellet; M-A John; L Scott; L Page-Shipp; H Dansey; T Victor; R Warren
Journal:  Int J Tuberc Lung Dis       Date:  2012-02       Impact factor: 2.373

7.  Antituberculosis drug resistance acquired during treatment: an analysis of cases reported in California, 1994-2006.

Authors:  Travis C Porco; Peter Oh; Jennifer M Flood
Journal:  Clin Infect Dis       Date:  2012-12-07       Impact factor: 9.079

8.  Diabetes is associated with drug-resistant tuberculosis in Eastern Taiwan.

Authors:  A-H Hsu; J-J Lee; C-Y Chiang; Y-H Li; L-K Chen; C-B Lin
Journal:  Int J Tuberc Lung Dis       Date:  2012-12-08       Impact factor: 2.373

9.  Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology.

Authors:  Danica Helb; Martin Jones; Elizabeth Story; Catharina Boehme; Ellen Wallace; Ken Ho; JoAnn Kop; Michelle R Owens; Richard Rodgers; Padmapriya Banada; Hassan Safi; Robert Blakemore; N T Ngoc Lan; Edward C Jones-López; Michael Levi; Michele Burday; Irene Ayakaka; Roy D Mugerwa; Bill McMillan; Emily Winn-Deen; Lee Christel; Peter Dailey; Mark D Perkins; David H Persing; David Alland
Journal:  J Clin Microbiol       Date:  2009-10-28       Impact factor: 5.948

10.  Availability of an assay for detecting Mycobacterium tuberculosis, including rifampin-resistant strains, and considerations for its use - United States, 2013.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-10-18       Impact factor: 17.586
View more
  5 in total

1.  Evaluation of OMNIgene Sputum and Ethanol Reagent for Preservation of Sputum Prior to Xpert and Culture Testing in Uganda.

Authors:  Elisa Ardizzoni; Patrick Orikiriza; Charles Ssuuna; Dan Nyehangane; Mourad Gumsboga; Ivan Mugisha Taremwa; Esther Turyashemererwa; Juliet Mwanga-Amumpaire; Céline Langendorf; Maryline Bonnet
Journal:  J Clin Microbiol       Date:  2019-12-23       Impact factor: 5.948

2.  Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results?

Authors:  Grant Theron; Rouxjeane Venter; Greg Calligaro; Liezel Smith; Jason Limberis; Richard Meldau; Duncan Chanda; Aliasgar Esmail; Jonny Peter; Keertan Dheda
Journal:  Clin Infect Dis       Date:  2016-02-16       Impact factor: 9.079

3.  Suboptimal specificity of Xpert MTB/RIF among treatment-experienced patients.

Authors:  John Z Metcalfe; Salome Makumbirofa; Beauty Makamure; Reggie Mutetwa; Renée A Peñaloza; Charles Sandy; Wilbert Bara; Stanley Mungofa; Philip C Hopewell; Peter Mason
Journal:  Eur Respir J       Date:  2015-03-18       Impact factor: 16.671

Review 4.  Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2018-08-27

5.  Xpert(®) MTB/RIF detection of rifampin resistance and time to treatment initiation in Harare, Zimbabwe.

Authors:  J Z Metcalfe; S Makumbirofa; B Makamure; C Sandy; W Bara; P Mason; P C Hopewell
Journal:  Int J Tuberc Lung Dis       Date:  2016-07       Impact factor: 2.373
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.